Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial

Overview

Journal Eurasian J Med

Publisher Aves

Specialty General Medicine

Date 2019 Nov 7

PMID 31692743

Citations 2

Authors

Zulfu Sertkaya

Fatih Ozkaya

Affiliations

Soon will be listed here.

Abstract

Objective: Nocebo effect is known in patients refered to side effects of drugs that cause more side effects than expected. Side effects on sexual function have been reported in about 60% of patients using silodosin. To investigate whether there was nocebo effect of silodosin in the side effects on sexual function.

Materials And Methods: Between May 2014 and March 2017, 129 moderate-to-severe LUTS patients were included in the study. For the patients, PSA (ng/mL), prostate volume (cc), uroflowmetry test IIEF-15 and IPSS questionnaires were filled at the time of before and after treatment. Patients were divided into two groups, referred to as side effects that was mentioned and not mentioned. After 3 months control, all patients were asked whether they had sexual side effects. It was analyzed whether there was significantly differences between two groups.

Results: The groups were compared in terms of the frequency of androgenic side effects, low semen volume was 40.9% in Group 1 and 22.2% in Group 2 (p=0.04). Anejaculation rates were 6% and 4%, respectively (p=0.12); loss of libido and erectile dysfunction were observed in one patient in both groups (p=0.42). There was no statistically significant difference between the groups for anejaculation, decreased libido and erectile dysfunction. 9 patients (7%) who left medication due to side effects were excluded from the study.

Conclusion: In patients, mentioned about the sexual side effects, low semen volume was seen more frequantly, but anejaculation, decreased libido and erectile dysfunction were same. Therefore, be informed about the side effects before treatment is a matter of debate.

Citing Articles

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A World J Urol. 2022; 40(8):2063-2070.

PMID: 35773357 PMC: 9279271. DOI: 10.1007/s00345-022-04071-7.

Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia-related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity.

Gul A, Coban S, Turkoglu A, Guzelsoy M, Ozturk M, Kankilic N Prostate Int. 2021; 8(4):152-157.

PMID: 33425792 PMC: 7767940. DOI: 10.1016/j.prnil.2020.04.002.

References

Walden P, Durkin M, Lepor H, Wetzel J, Gluchowski C, Gustafson E . Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol. 1997; 157(3):1032-8. View

Costabile R, Steers W . How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?. J Sex Med. 2006; 3(4):676-681. DOI: 10.1111/j.1743-6109.2006.00274.x. View

Chapple C, Montorsi F, Tammela T, Wirth M, Koldewijn E, Fernandez Fernandez E . Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2010; 59(3):342-52. DOI: 10.1016/j.eururo.2010.10.046. View

Hauser W, Hansen E, Enck P . Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012; 109(26):459-65. PMC: 3401955. DOI: 10.3238/arztebl.2012.0459. View

Yokoyama T, Hara R, Fukumoto K, Fujii T, Jo Y, Miyaji Y . Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol. 2011; 18(3):225-30. DOI: 10.1111/j.1442-2042.2010.02708.x. View

Rosen R, Giuliano F, Carson C . Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005; 47(6):824-37. DOI: 10.1016/j.eururo.2004.12.013. View

Enck P, Benedetti F, Schedlowski M . New insights into the placebo and nocebo responses. Neuron. 2008; 59(2):195-206. DOI: 10.1016/j.neuron.2008.06.030. View

Kobayashi K, Masumori N, Kato R, Hisasue S, Furuya R, Tsukamoto T . Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration. Int J Impot Res. 2009; 21(5):306-10. PMC: 2834370. DOI: 10.1038/ijir.2009.27. View

Hahn R . The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med. 1997; 26(5 Pt 1):607-11. DOI: 10.1006/pmed.1996.0124. View

10.

Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat S . Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014; 11(6):1554-66. DOI: 10.1111/jsm.12525. View

11.

Benedetti F, Lanotte M, Lopiano L, Colloca L . When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007; 147(2):260-71. DOI: 10.1016/j.neuroscience.2007.02.020. View

12.

Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A . Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. J Sex Med. 2007; 4(6):1708-12. DOI: 10.1111/j.1743-6109.2007.00563.x. View

13.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L . Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61(5):917-25. DOI: 10.1016/j.eururo.2012.01.013. View

14.

Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan S, Maggi M . Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011; 60(4):809-25. DOI: 10.1016/j.eururo.2011.06.037. View

15.

Roehrborn C, Kaplan S, Lepor H, Volinn W . Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2010; 14(2):143-8. PMC: 3094762. DOI: 10.1038/pcan.2010.46. View

16.

Capitanio U, Salonia A, Briganti A, Montorsi F . Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013; 67(6):544-51. DOI: 10.1111/ijcp.12135. View

17.

McMahon C, Jannini E, Waldinger M, Rowland D . Standard operating procedures in the disorders of orgasm and ejaculation. J Sex Med. 2012; 10(1):204-29. DOI: 10.1111/j.1743-6109.2012.02824.x. View

18.

El-Sakka A . Lower urinary tract symptoms in patients with erectile dysfunction: analysis of risk factors. J Sex Med. 2006; 3(1):144-9. DOI: 10.1111/j.1743-6109.2005.00132.x. View

19.

Barsky A, Saintfort R, Rogers M, Borus J . Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002; 287(5):622-7. DOI: 10.1001/jama.287.5.622. View